Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock
Key Points
The transaction involved 2,203 shares at $532.08 per share for a total value of ~$1.2 million.
The director traded shares equal to 23% of the stake held before the filing.
The direct sale followed a same-day exercise of 2,203 options at a strike price of $114.17.
The move occurred as the stock recorded a -16% one-year return as of the Sept. 4, 2026, transaction date.
Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Sept. 4, 2026, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $1.2 million |
| Shares sold (Directly held) | 2,203 |
| Post-transaction shares (Directly held) | 9,568 |
| Post-transaction value | $5.12 million |
Transaction value based on SEC Form 4 weighted average sale price ($532.08); post-transaction value based on Sept. 04, 2026, market close ($535.38).
Key questions
- What was the structure of the transaction?
Lawrence D. Kingsley executed an exercise-and-sell transaction, converting 2,203 options into common stock at $114.17 per share before immediately disposing of them at a weighted average price of $532.08. - How does this disposal impact the director's total equity position?
The director's direct ownership of 9,568 shares of common stock remains unchanged from the pre-transaction level, as the shares sold were newly issued through the exercise of the option. - What is the scale of the company's operations?
Headquartered in Westbrook, IDEXX Laboratories operates as a global enterprise with 11,000 employees and reported a trailing-twelve-month net income of $1.1 billion. - Does the insider retain further equity exposure?
The director continues to hold 9,568 shares directly, representing a 0.0121% ownership stake with a market value of $5.12 million as of the Sept. 4, 2026, valuation.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-09) | $515.15 |
| Market Capitalization | $41.0 billion |
| Revenue (TTM) | $4.6 billion |
| Net Income (TTM) | $1.1 billion |
Company Snapshot
- IDEXX Laboratories develops, manufactures, and distributes a comprehensive portfolio of diagnostic products, software solutions, and services, primarily serving companion animal veterinary practices, with additional revenue streams from livestock, poultry, and dairy operations, as well as the water quality testing sector.
- The company generates revenue through the sale of diagnostic instruments, consumables, software platforms, and related services, leveraging its proprietary technology and established distribution networks to capture recurring revenue from its installed customer base.
- IDEXX's primary customers include veterinary clinics and animal health practitioners globally, agricultural producers in the livestock and dairy sectors, and water quality testing laboratories, with a strategic focus on companion animal diagnostics as its largest revenue contributor.
IDEXX Laboratories is a global leader in animal diagnostics and software solutions, with a market capitalization of $41.0 billion and TTM revenue of $4.6 billion. The company maintains a diversified business model spanning companion animal, livestock, poultry, dairy, and water quality segments, generating substantial recurring revenue through diagnostic consumables and software subscriptions. IDEXX's competitive advantages include its proprietary diagnostic technology platform, extensive installed base of veterinary clinics, and integrated software ecosystem that creates switching costs and enhances customer retention.
What this transaction means for investors
Director Kingsley's transaction is a pretty standard exercise-and-sell event, fairly typical among insiders, so investors shouldn't be running for the exits on this news. While the $1.2 million sale looks sizable, Kingsley still holds over $5 million in shares afterward, as well, so they still have plenty of "skin in the game" with IDXX stock.
As for IDEXX Labs' operations, the company continues to fire on all cylinders with sales and EPS growing by 10% and 18% in the last quarter. This stable, double-digit growth is nothing new for the company, which is part of what makes it one of my favorite stocks to own and a core holding for my daughter as well. Now building a suite of cancer diagnostics solutions, IDEXX remains well-positioned to continue this growth for years (if not decades) to come. With a large installed base of equipment worldwide supporting a razor-and-blade model, IDEXX Labs has a wide moat.
However, despite the company's rosy outlook, in my opinion, IDXX shares have struggled over the last few years as it couldn't live up to a perilously high valuation. Now following a 30% drop from its 52-week high, IDEXX trades at 33 times FCF -- which is its lowest mark of the last decade -- and half of its 10-year average of 66. This combination of a much more reasonable valuation and continuously steady, double-digit sales and EPS growth makes IDEXX an excellent buy at today's price, and I look forward to buying more shares for my daughter as well.
Josh Kohn-Lindquist has positions in Idexx Laboratories. The Motley Fool has positions in and recommends Idexx Laboratories. The Motley Fool has a disclosure policy.